| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mesothelioma | 37 | 2023 | 311 | 9.130 |
Why?
|
| Pleural Neoplasms | 26 | 2022 | 188 | 7.540 |
Why?
|
| Lung Neoplasms | 49 | 2023 | 2262 | 5.700 |
Why?
|
| Tomography, X-Ray Computed | 52 | 2022 | 2601 | 5.220 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 24 | 2023 | 466 | 3.360 |
Why?
|
| Radiography, Thoracic | 22 | 2021 | 320 | 3.050 |
Why?
|
| Solitary Pulmonary Nodule | 19 | 2015 | 138 | 3.010 |
Why?
|
| Radiographic Image Enhancement | 22 | 2015 | 462 | 2.950 |
Why?
|
| Lung | 27 | 2021 | 1170 | 2.870 |
Why?
|
| Diagnostic Imaging | 12 | 2023 | 469 | 2.850 |
Why?
|
| Algorithms | 28 | 2023 | 1830 | 2.330 |
Why?
|
| Artificial Intelligence | 15 | 2023 | 298 | 2.270 |
Why?
|
| Diagnosis, Computer-Assisted | 19 | 2023 | 332 | 2.160 |
Why?
|
| Physics | 3 | 2023 | 22 | 2.020 |
Why?
|
| Image Processing, Computer-Assisted | 20 | 2014 | 1204 | 2.010 |
Why?
|
| Radiology | 10 | 2023 | 194 | 2.000 |
Why?
|
| Pattern Recognition, Automated | 14 | 2013 | 217 | 1.770 |
Why?
|
| Subtraction Technique | 8 | 2013 | 133 | 1.500 |
Why?
|
| Radiologists | 3 | 2021 | 46 | 1.410 |
Why?
|
| Health Physics | 3 | 2023 | 18 | 1.390 |
Why?
|
| Observer Variation | 17 | 2014 | 602 | 1.320 |
Why?
|
| Tumor Burden | 10 | 2016 | 289 | 1.240 |
Why?
|
| Neoplasm Staging | 13 | 2022 | 1939 | 1.240 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 4 | 2019 | 56 | 1.140 |
Why?
|
| Biomedical Research | 4 | 2020 | 376 | 1.090 |
Why?
|
| Databases, Factual | 6 | 2011 | 814 | 1.070 |
Why?
|
| Humans | 108 | 2023 | 86643 | 0.990 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 3 | 2009 | 17 | 0.960 |
Why?
|
| Radiology Information Systems | 7 | 2020 | 76 | 0.920 |
Why?
|
| Lung Diseases | 7 | 2006 | 263 | 0.910 |
Why?
|
| Reproducibility of Results | 28 | 2023 | 2705 | 0.890 |
Why?
|
| Periodicals as Topic | 3 | 2016 | 168 | 0.890 |
Why?
|
| Image Interpretation, Computer-Assisted | 8 | 2018 | 663 | 0.880 |
Why?
|
| Sensitivity and Specificity | 26 | 2015 | 1991 | 0.860 |
Why?
|
| Aged, 80 and over | 28 | 2019 | 6509 | 0.860 |
Why?
|
| Radionuclide Imaging | 5 | 2018 | 220 | 0.820 |
Why?
|
| Tomography, Spiral Computed | 4 | 2005 | 76 | 0.790 |
Why?
|
| Computer-Assisted Instruction | 1 | 2020 | 43 | 0.730 |
Why?
|
| Aged | 39 | 2019 | 18415 | 0.700 |
Why?
|
| Databases as Topic | 7 | 2007 | 92 | 0.680 |
Why?
|
| Pleura | 1 | 2018 | 30 | 0.670 |
Why?
|
| Middle Aged | 41 | 2023 | 25028 | 0.630 |
Why?
|
| Publications | 1 | 2018 | 27 | 0.630 |
Why?
|
| Societies, Scientific | 1 | 2018 | 44 | 0.620 |
Why?
|
| Medicine | 1 | 2018 | 89 | 0.600 |
Why?
|
| Public Opinion | 3 | 2022 | 43 | 0.590 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 1169 | 0.590 |
Why?
|
| Male | 46 | 2023 | 40965 | 0.590 |
Why?
|
| Female | 48 | 2023 | 44532 | 0.590 |
Why?
|
| Image Enhancement | 4 | 2008 | 563 | 0.570 |
Why?
|
| Professional Competence | 4 | 2013 | 68 | 0.560 |
Why?
|
| Radiography | 5 | 2023 | 813 | 0.560 |
Why?
|
| ROC Curve | 13 | 2015 | 752 | 0.550 |
Why?
|
| Early Detection of Cancer | 5 | 2023 | 394 | 0.530 |
Why?
|
| Mass Screening | 6 | 2023 | 618 | 0.530 |
Why?
|
| Tomography, Emission-Computed | 2 | 2016 | 103 | 0.450 |
Why?
|
| Access to Information | 1 | 2013 | 27 | 0.440 |
Why?
|
| Positron-Emission Tomography | 4 | 2022 | 329 | 0.440 |
Why?
|
| Editorial Policies | 1 | 2013 | 32 | 0.440 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 2438 | 0.420 |
Why?
|
| Risk Assessment | 1 | 2019 | 2261 | 0.400 |
Why?
|
| Software | 5 | 2013 | 654 | 0.380 |
Why?
|
| Retrospective Studies | 19 | 2019 | 8489 | 0.380 |
Why?
|
| Artifacts | 2 | 2009 | 244 | 0.360 |
Why?
|
| Adult | 28 | 2019 | 25648 | 0.350 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 379 | 0.350 |
Why?
|
| Thorax | 2 | 2020 | 75 | 0.350 |
Why?
|
| Reference Standards | 5 | 2013 | 159 | 0.330 |
Why?
|
| Thoracic Diseases | 1 | 2008 | 25 | 0.320 |
Why?
|
| Survival Rate | 5 | 2019 | 1863 | 0.320 |
Why?
|
| Quality Assurance, Health Care | 4 | 2017 | 220 | 0.310 |
Why?
|
| Forecasting | 1 | 2008 | 304 | 0.300 |
Why?
|
| Cluster Analysis | 4 | 2005 | 369 | 0.300 |
Why?
|
| Congresses as Topic | 2 | 2018 | 116 | 0.290 |
Why?
|
| Machine Learning | 3 | 2023 | 232 | 0.290 |
Why?
|
| False Positive Reactions | 7 | 2009 | 216 | 0.290 |
Why?
|
| Mass Chest X-Ray | 1 | 2006 | 6 | 0.290 |
Why?
|
| Peritoneal Neoplasms | 2 | 2022 | 177 | 0.280 |
Why?
|
| Quality Control | 5 | 2013 | 117 | 0.280 |
Why?
|
| Radiation Pneumonitis | 2 | 2017 | 21 | 0.280 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 3362 | 0.270 |
Why?
|
| Contrast Media | 1 | 2011 | 1078 | 0.270 |
Why?
|
| Treatment Outcome | 7 | 2019 | 7993 | 0.270 |
Why?
|
| Intestines | 1 | 2009 | 411 | 0.270 |
Why?
|
| United States | 8 | 2022 | 6672 | 0.260 |
Why?
|
| Phantoms, Imaging | 3 | 2018 | 429 | 0.260 |
Why?
|
| Imaging, Three-Dimensional | 7 | 2017 | 579 | 0.260 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2018 | 176 | 0.260 |
Why?
|
| Publishing | 1 | 2016 | 90 | 0.250 |
Why?
|
| Rhinitis | 2 | 2017 | 175 | 0.240 |
Why?
|
| Sinusitis | 2 | 2017 | 210 | 0.240 |
Why?
|
| Emphysema | 1 | 2023 | 22 | 0.220 |
Why?
|
| Pulmonary Emphysema | 1 | 2023 | 30 | 0.220 |
Why?
|
| Patient Care | 1 | 2023 | 100 | 0.210 |
Why?
|
| Follow-Up Studies | 5 | 2013 | 3640 | 0.210 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2015 | 294 | 0.210 |
Why?
|
| Prognosis | 4 | 2018 | 3679 | 0.190 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 86 | 0.190 |
Why?
|
| Systematized Nomenclature of Medicine | 1 | 2020 | 2 | 0.190 |
Why?
|
| Information Storage and Retrieval | 3 | 2006 | 120 | 0.190 |
Why?
|
| Health | 1 | 2020 | 29 | 0.190 |
Why?
|
| Lymphatic Metastasis | 2 | 2015 | 486 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 1036 | 0.180 |
Why?
|
| Angiography | 2 | 2014 | 208 | 0.180 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 1565 | 0.170 |
Why?
|
| Data Collection | 2 | 2013 | 372 | 0.170 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 110 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 127 | 0.170 |
Why?
|
| Health Resources | 1 | 2019 | 76 | 0.160 |
Why?
|
| International Cooperation | 1 | 2018 | 127 | 0.160 |
Why?
|
| Ribs | 1 | 1998 | 45 | 0.160 |
Why?
|
| Diaphragm | 1 | 1998 | 50 | 0.160 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2018 | 56 | 0.160 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 2903 | 0.160 |
Why?
|
| Automation | 3 | 2006 | 106 | 0.160 |
Why?
|
| Risk | 1 | 2019 | 674 | 0.160 |
Why?
|
| Illinois | 1 | 2019 | 462 | 0.150 |
Why?
|
| Clinical Competence | 2 | 2022 | 751 | 0.150 |
Why?
|
| Paranasal Sinuses | 1 | 2017 | 60 | 0.150 |
Why?
|
| Lung Volume Measurements | 2 | 2013 | 19 | 0.150 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 2360 | 0.140 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2016 | 34 | 0.140 |
Why?
|
| United Kingdom | 1 | 2016 | 164 | 0.140 |
Why?
|
| Time Factors | 4 | 2009 | 5210 | 0.140 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2016 | 64 | 0.130 |
Why?
|
| Regression Analysis | 4 | 2015 | 596 | 0.130 |
Why?
|
| Pandemics | 1 | 2021 | 740 | 0.130 |
Why?
|
| Neuroblastoma | 1 | 2018 | 374 | 0.130 |
Why?
|
| Deoxycytidine | 2 | 2012 | 237 | 0.120 |
Why?
|
| Biomarkers | 3 | 2021 | 1718 | 0.120 |
Why?
|
| Radiation Dosage | 4 | 2017 | 227 | 0.120 |
Why?
|
| Pulmonary Embolism | 1 | 1997 | 222 | 0.120 |
Why?
|
| Colonic Polyps | 2 | 2008 | 126 | 0.120 |
Why?
|
| Knowledge Bases | 3 | 2007 | 14 | 0.120 |
Why?
|
| Bias | 1 | 2014 | 127 | 0.120 |
Why?
|
| Cisplatin | 2 | 2012 | 612 | 0.120 |
Why?
|
| Anatomic Landmarks | 1 | 2013 | 31 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2022 | 1004 | 0.110 |
Why?
|
| Diagnostic Errors | 3 | 2002 | 160 | 0.110 |
Why?
|
| Radiopharmaceuticals | 2 | 2018 | 180 | 0.110 |
Why?
|
| Pemetrexed | 1 | 2012 | 76 | 0.110 |
Why?
|
| Glutamates | 1 | 2012 | 89 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2017 | 138 | 0.110 |
Why?
|
| Fractals | 1 | 2012 | 42 | 0.110 |
Why?
|
| Educational Status | 1 | 2013 | 188 | 0.110 |
Why?
|
| Fourier Analysis | 1 | 2012 | 125 | 0.110 |
Why?
|
| Disease Progression | 4 | 2019 | 1531 | 0.110 |
Why?
|
| Attitude | 1 | 2013 | 127 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 321 | 0.110 |
Why?
|
| Pulmonary Artery | 1 | 2014 | 306 | 0.110 |
Why?
|
| Thoracic Neoplasms | 2 | 2019 | 64 | 0.110 |
Why?
|
| Guanine | 1 | 2012 | 208 | 0.100 |
Why?
|
| Child | 2 | 2020 | 6927 | 0.100 |
Why?
|
| Multidetector Computed Tomography | 1 | 2012 | 54 | 0.100 |
Why?
|
| Pulmonary Atelectasis | 1 | 2010 | 18 | 0.100 |
Why?
|
| Bone and Bones | 1 | 2012 | 265 | 0.100 |
Why?
|
| Pneumonia | 1 | 2012 | 179 | 0.100 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2010 | 44 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 346 | 0.090 |
Why?
|
| Models, Theoretical | 2 | 2017 | 482 | 0.090 |
Why?
|
| Adolescent | 4 | 2018 | 8981 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2012 | 397 | 0.090 |
Why?
|
| Xenon Radioisotopes | 2 | 2000 | 10 | 0.090 |
Why?
|
| Ventilation-Perfusion Ratio | 2 | 2000 | 13 | 0.090 |
Why?
|
| Mammography | 2 | 2023 | 463 | 0.080 |
Why?
|
| Young Adult | 4 | 2018 | 5976 | 0.080 |
Why?
|
| Lymphangiogenesis | 1 | 2008 | 38 | 0.080 |
Why?
|
| Europe | 1 | 2009 | 309 | 0.080 |
Why?
|
| Chicago | 1 | 2012 | 1379 | 0.080 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2008 | 81 | 0.070 |
Why?
|
| Task Performance and Analysis | 1 | 2006 | 86 | 0.070 |
Why?
|
| Photons | 1 | 2006 | 46 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2015 | 334 | 0.070 |
Why?
|
| Body Weights and Measures | 1 | 2005 | 27 | 0.070 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2006 | 127 | 0.070 |
Why?
|
| Consensus | 2 | 2019 | 335 | 0.060 |
Why?
|
| Quality of Life | 3 | 2018 | 1585 | 0.060 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2004 | 33 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 1673 | 0.060 |
Why?
|
| Computers | 1 | 2023 | 112 | 0.060 |
Why?
|
| Radiotherapy Dosage | 2 | 2015 | 468 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 322 | 0.060 |
Why?
|
| Remission Induction | 1 | 2005 | 722 | 0.060 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2004 | 201 | 0.060 |
Why?
|
| DNA Helicases | 1 | 2023 | 79 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2017 | 971 | 0.060 |
Why?
|
| Benchmarking | 1 | 2023 | 78 | 0.050 |
Why?
|
| Ascites | 1 | 2022 | 55 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 302 | 0.050 |
Why?
|
| Mentors | 1 | 2022 | 76 | 0.050 |
Why?
|
| Students | 1 | 2022 | 147 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 456 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 1075 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2019 | 70 | 0.040 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2019 | 63 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 172 | 0.040 |
Why?
|
| Physicians | 1 | 2006 | 673 | 0.040 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2018 | 19 | 0.040 |
Why?
|
| Organs at Risk | 1 | 2018 | 41 | 0.040 |
Why?
|
| Pleural Effusion | 1 | 1998 | 45 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 369 | 0.040 |
Why?
|
| Nurse-Patient Relations | 1 | 2017 | 13 | 0.040 |
Why?
|
| Genomics | 1 | 2023 | 720 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2019 | 279 | 0.040 |
Why?
|
| Pneumonectomy | 1 | 2019 | 196 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 1801 | 0.040 |
Why?
|
| Animals | 1 | 2015 | 26582 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 865 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 429 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 357 | 0.030 |
Why?
|
| Nasal Mucosa | 1 | 2015 | 186 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 2271 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2013 | 4213 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2501 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 751 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1686 | 0.030 |
Why?
|
| Communication | 1 | 2017 | 441 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 912 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 1186 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 610 | 0.030 |
Why?
|
| Placebos | 1 | 2012 | 218 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 3046 | 0.030 |
Why?
|
| Decision Making | 1 | 2017 | 642 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2018 | 3612 | 0.030 |
Why?
|
| Research Design | 1 | 2015 | 594 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2012 | 281 | 0.020 |
Why?
|
| Education, Medical | 1 | 2013 | 233 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2013 | 572 | 0.020 |
Why?
|
| Inflammation | 1 | 2015 | 920 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 1204 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2008 | 44 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 78 | 0.020 |
Why?
|
| Vesicular Transport Proteins | 1 | 2008 | 63 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 1823 | 0.020 |
Why?
|
| Calibration | 1 | 2007 | 99 | 0.020 |
Why?
|
| Database Management Systems | 1 | 2007 | 41 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 407 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 930 | 0.020 |
Why?
|
| Motion | 1 | 2006 | 85 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 860 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2006 | 105 | 0.020 |
Why?
|
| Fuzzy Logic | 1 | 2005 | 15 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1464 | 0.020 |
Why?
|
| Expert Systems | 1 | 2003 | 18 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 238 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 1376 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 1169 | 0.010 |
Why?
|
| Risk Factors | 1 | 2002 | 5417 | 0.010 |
Why?
|